Loading...
Loading...
PRTA| Name | Value |
|---|---|
| Revenues | 84.9M |
| Cost of Revenue | 2.3M |
| Gross Profit | 82.6M |
| Operating Expense | 74.6M |
| Operating I/L | 10.3M |
| Other Income/Expense | 8.5M |
| Interest Income | 8.5M |
| Pretax | 18.8M |
| Income Tax Expense | -3.1M |
| Net Income/Loss | 21.9M |
Prothena Corporation plc is a late-stage clinical company in the United States, specializing in the discovery and development of novel therapies for life-threatening diseases. The company's primary focus is on the development of investigational humanized antibodies, including Birtamimab for AL amyloidosis, Prasinezumab for Parkinson's disease, PRX004 for Transthyretin amyloidosis, and PRX005 for Alzheimer's disease. Additionally, Prothena has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies targeting alpha-synuclein, as well as a collaboration agreement with Bristol-Myers Squibb to develop antibodies.
